Recurrent Non-small Cell Lung Cancer: Evaluation of CT-guided Radiofrequency Ablation As Salvage Therapy
Overview
Authors
Affiliations
Background: Radiofrequency ablation (RFA) is a potential application as a salvage tool after failure of surgery, chemotherapy, or radiotherapy of non-small cell lung cancer (NSCLC). Although several studies have evaluated the use of RFA in primary NSCLC, there is little literature on its potential application as a salvage tool.
Purpose: To evaluate CT-guided RFA employed as a salvage therapy for pulmonary recurrences of NSCLC after prior treatment with chemotherapy, radiation therapy, and/or surgery.
Material And Methods: A retrospective computer database search yielded 33 patients with biopsy proven primary NSCLC who underwent CT-guided RFA of 39 recurrent tumors following surgery, chemotherapy, and/or radiotherapy. Follow-up imaging was performed with CT and PET-CT. The endpoints of interest were progression-free survival (PFS) and time to local progression (TTLP). PFS and TTLP were compared by lesion size (<3 cm, ≥3 cm).
Results: The median PFS was 8 months. For patients with a tumor size <3 cm median PFS was 11 months, whereas the median PFS of patients with a tumor size ≥3 cm was 5 months. The difference did not reach statistical significance (P = 0.09). The median TTLP of all tumors was 14 months. TTLP of ablated tumors <3 cm in size was 24 months, compared to 8 months for ablated tumors ≥3 cm in size. The difference did not reach statistical significance (P = 0.07).
Conclusion: RFA of recurrent NSCLC may be a valuable salvage tool to achieve local tumor control, especially in tumors measuring <3 cm in size.
Bonome P, Pezzulla D, Lancellotta V, Scrofani A, Macchia G, Rodolfino E Cancers (Basel). 2023; 15(24).
PMID: 38136413 PMC: 10741973. DOI: 10.3390/cancers15245869.
Zhao Q, Wang J, Fu Y, Hu B Thorac Cancer. 2023; 14(32):3181-3190.
PMID: 37740563 PMC: 10643797. DOI: 10.1111/1759-7714.15114.
Liu B Zhongguo Fei Ai Za Zhi. 2023; 26(3):238-244.
PMID: 37035886 PMC: 10106791. DOI: 10.3779/j.issn.1009-3419.2023.106.06.
Ghosn M, Solomon S Cancers (Basel). 2021; 13(20).
PMID: 34680348 PMC: 8534236. DOI: 10.3390/cancers13205202.
Dickhoff C, Rodriguez Schaap P, Otten R, Heymans M, Heineman D, Dahele M Ther Adv Med Oncol. 2018; 10:1758835918787989.
PMID: 30023008 PMC: 6047243. DOI: 10.1177/1758835918787989.